Positive top-line Phase IIb for Lipid Therapeutics' ulcerative colitis drug
This article was originally published in Scrip
Executive Summary
Lipid Therapeutics is taking steps to progress its lead product, a controlled release formulation of phosphatidylcholine, LT-02, into Phase III after reporting positive top-line Phase IIb results for the product in patients with ulcerative colitis.